Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004037 | 0.81 | ALDH1A1 (0.63) | TAS1R3TAS1R1TAS1R2CYP1A2CYP2C9 | |
| SCHEMBL4169560 | 0.80 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2CYP1A2CYP2C9 | |
| SCHEMBL4141231 | 0.79 | L3MBTL1 (0.50) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KDM4E | |
| SCHEMBL24574912 | 0.79 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2CYP1A2CYP2C9 | |
| SCHEMBL1003870 | 0.77 | GAA (0.54) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KDM4E | |
| SCHEMBL13753819 | 0.76 | KDM4E (0.58) | SMN1; SMN2KDM4ELMNAHPGDHTT | |
| SCHEMBL5800687 | 0.76 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KDM4E | |
| SCHEMBL354669 | 0.76 | ALDH1A1 (0.52) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KDM4E | |
| SCHEMBL10073270 | 0.75 | NR1H4 (0.44) | CYP1A2CYP2C9SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4156165 | 0.75 | SMN1; SMN2 (0.64) | TAS1R3TAS1R1TAS1R2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7453011-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6982351-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1453787-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL Biomedical Corporation (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003050072-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL BIOMEDICAL CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | TAS1R3 1003/4885TAS1R1 1566/4885TAS1R2 1343/4885 |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TAS1R3 3904/4885TAS1R1 3468/4885TAS1R2 3722/4885 |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TAS1R3 3904/4885TAS1R1 3468/4885TAS1R2 3722/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | TAS1R3 2726/4885TAS1R1 2426/4885TAS1R2 2105/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | TAS1R3 3904/4885TAS1R1 3468/4885TAS1R2 3722/4885 |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | POU2F1, POU2F2, POF1B | TAS1R3 1003/4885TAS1R1 1566/4885TAS1R2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.